Novel Imaging Biomarkers in Drug Induced Interstitial Lung Diseases
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: closed (25 October 2021) | Viewed by 7405
Special Issue Editor
Interests: Interstitial Lung Disease (ILD); diagnosis; management; idiopathic pulmonary fibrosis; sarcoidosis; hypersensitivity pneumonitis; drug-induced toxicity; drug-induced ILDs (TRISTAN)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Drug-Induced Interstitial Lung Diseases (DI-ILDs) are an emerging complication of the ever-expanding field of drug therapies in oncological and immunological care. DI-ILD can be caused by over 350 different drugs. The incidence and prevalence is perceived to be on the rise due to the increasing number of oncological and immunotherapies. The clinical phenotype, imaging, and histopathological features are highly variable and are often difficult to distinguish from pre-existing ILDs or co-existing infections. DI-ILD is often therefore a diagnosis of exclusion and thus its diagnosis can be challenging. Sensitive and specific biomarkers are required to evaluate DI-ILD during drug development. In particular, there is a need to detect early signs of DI-ILD, as often symptoms present too late, when there is significant radiological evidence of lung injury. Recent advances in lung imaging methods may provide us with an opportunity to develop more sensitive and specific biomarkers for DI-ILD.
This Special Issue will present the work of scientific and imaging experts within the fields of MRI, CT, and PET. The reader will be presented with the most up-to-date, state-of-the-art, novel imaging research exploring the utility of these techniques in the early identification and diagnosis of DI-ILD.
Dr. Nazia Chaudhuri
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug toxicity
- interstitial lung disease
- lung imaging
- MRI
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.